CTOs on the Move

Daiichi Sankyo

www.dsi.com

 
Daiichi Sankyo, Inc. headquartered in Parsippany, New Jersey, is the U.S. subsidiary of Daiichi Sankyo, Co., Ltd. and a member of the Daiichi Sankyo Group. Global clinical development and regulatory activities are headquartered at Daiichi Sankyo Pharma Development in Edison, New Jersey. Our team of more than 1,400 U.S. employees is dedicated to the creation and supply of innovative pharmaceutical products to address diversified, unmet medical needs. We currently market therapies in hypertension, thrombotic disorders, stroke risk reduction, dyslipidemia, diabetes, acute coronary syndrome, opioid-induced constipation and metastatic melanoma. With over 100 years of scientific expertise and a presence in more ...
  • Number of Employees: 10K-50K
  • Annual Revenue: $500M-1 Billion
  • www.dsi.com
  • 211 Mt. Airy Road
    Basking Ridge, NJ USA 07920
  • Phone: 908.992.6400

Executives

Name Title Contact Details
Paulette Gangemi
Senior Director, Employee Relations and Employment Practices (HR) Profile

Similar Companies

Acrometrix

Acrometrix is a Benicia, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

DiNovo

DiNovo is a distributor of USP <797> <71> <800> compliance products, packaging solutions, and infusion supplies. We are designed to bring innovative products at a low cost to the healthcare market place.

ParaTechs

ParaTechs is a Lexington, KY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Pathwork Diagnostics

Pathwork Diagnostics is a Redwood City, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Metacrine

We are a clinical-stage biopharmaceutical company focused on discovering and developing best-in-class therapies for patients with liver and gastrointestinal, or GI, diseases. Since our founding in 2014, we have invested in building a foundation of chemistry and biology expertise to drive innovative drug discovery and development. We believe these internal capabilities allow us to gain insights into disease targets and mechanisms and more quickly and purposefully design therapies with characteristics that we view as key to safety and efficacy. With this systematic approach, we have designed novel, proprietary farnesoid X receptor (FXR) clinical product candidates arising from a unique chemical scaffold with the potential to be best-in-class for non-alcoholic steatohepatitis, or NASH, and first- in-class for Inflammatory Bowel Disease, or IBD. In addition to our FXR program, we have continued to invest in drug discovery on other therapeutic targets that have effects on inflammation and/or fibrosis for which we believe we could develop proprietary small molecule therapies.